Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aripiprazole and suicidality.

Laurent Holzer1, Chin B Eap

  • 1Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (SUPEA), Centre Thérapeutique de Jour pour Adolescents, Lausanne, Switzerland. laurent.holzer@chuv.ch

International Clinical Psychopharmacology
|January 20, 2006
PubMed
Summary

Aripiprazole treatment may increase suicide risk in some patients. A 19-year-old experienced suicidal behavior after switching to aripiprazole, suggesting a potential link to the antipsychotic medication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.

Pharmacopsychiatry·2026
Same author

Inhibition of stress resilience and adult hippocampal neurogenesis by platelet-derived LPA16:0 in anxiety.

Nature communications·2026
Same author

Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses.

Molecular psychiatry·2025
Same author

Childhood trauma and relationship with the parents: associations with lipids, glucose, and prolactin levels during antipsychotic treatment in patients with first-episode psychosis.

Frontiers in psychiatry·2025
Same author

Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole.

Schizophrenia bulletin·2025
Same author

Therapeutic Reference Range for Clozapine Plasma Levels in Parkinson's Disease or Dementia: A Systematic Review and Individual Participant Data Meta-analysis.

Pharmacopsychiatry·2025

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Case Study

Background:

  • Aripiprazole is an atypical antipsychotic used to treat psychosis.
  • Previous reports suggest aripiprazole can worsen psychotic symptoms.
  • The safety profile regarding suicidal behavior requires further investigation.

Observation:

  • A 19-year-old patient switched from risperidone to aripiprazole.
  • The patient exhibited no prior suicidal or aggressive behavior.
  • Suicidal behavior recurred four weeks after initiating aripiprazole.

Findings:

  • The patient's suicidal behavior emerged after starting aripiprazole.
  • Suicidal ideation and attempts were not present before or after aripiprazole treatment.
  • A temporal association suggests aripiprazole may have increased suicide risk.

Related Experiment Videos

Implications:

  • This case highlights a potential, previously unreported adverse effect of aripiprazole.
  • Clinicians should carefully monitor patients, especially young adults, for suicidal behavior during aripiprazole treatment.
  • Further research is needed to confirm the association between aripiprazole and increased suicide risk.